Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2006Thrombosis and Haemostasis

The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders

View Full Paper
Ask AI
Bookmark
Share

Authors

DVDino VeneriUniversity of Verona
Giuseppe Lippi
Giuseppe LippiUniversità Cattolica del Sacro CuoreRSRachel StennerFondazione Salvatore Maugeri

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Veneri et al. (2006) studied this question.

synapsesocial.com/papers/6a1be8260a1f7575939d2ba2https://doi.org/10.1160/th06-06-0317
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura2001 · 551 citations
  2. 2Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease2001 · 110 citations
  3. 3Rituximab for the Treatment of High Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy.2005 · 3 citations
  4. 4Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases2004 · 39 citations